GFM
CGEM icon

GF Fund Management’s Cullinan Oncology CGEM Stock Holding History

GF Fund Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.8K Sell
1,252
-66
-5% -$980 ﹤0.01% 474
2026
Q1 		$18.7K Buy
1,318
+158
+14% +$2.03K ﹤0.01% 506
2025
Q4 		$12K Sell
1,160
-91
-7% -$821 ﹤0.01% 563
2025
Q3 		$7.42K Sell
1,251
-240
-16% -$1.76K ﹤0.01% 577
2025
Q2 		$11.2K Hold
1,491
– – ﹤0.01% 559
2025
Q1 		$11.3K Buy
1,491
+268
+22% +$2.57K ﹤0.01% 549
2024
Q4 		$14.9K Buy
+1,223
New +$17.6K ﹤0.01% 497

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

GF Fund Management's CGEM Position: Q2 2026 in Review

GF Fund Management reduced its Cullinan Oncology (CGEM) stake by 5% in Q2 2026, selling an estimated $980 and leaving 1,252 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #474.

GF Fund Management first reported a position in CGEM in Q4 2024 and has held it in 7 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • GF Fund Management held 1,252 shares of Cullinan Oncology worth $22.8K as of Q2 2026.
  • GF Fund Management sold 66 Cullinan Oncology shares in Q2 2026, an estimated $980.
  • Cullinan Oncology made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #474 holding.
  • GF Fund Management first reported a position in Cullinan Oncology in Q4 2024 and has held it in 7 quarters since.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.